Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 7301 - 7325 of 8039 in total
LGH-447 is under investigation in clinical trial NCT02160951 (Dose Escalation Study of LGH447 in Japanese Patients With Relapsed and/or Refractory Hematologic Malignancies).
Investigational
Matched Description: … LGH-447 is under investigation in clinical trial NCT02160951 (Dose Escalation Study of LGH447 in Japanese …
PRI-724 is under investigation in clinical trial NCT03620474 (Safety and Effectiveness of PRI-724 for Hepatitis C or B Virus Derived Liver Cirrhosis).
Investigational
Matched Description: … PRI-724 is under investigation in clinical trial NCT03620474 (Safety and Effectiveness of PRI-724 for …
TP-271 is under investigation in clinical trial NCT02724085 (A Phase 1 Study to Assess the Safety, Tolerability and PK of IV TP-271).
Investigational
Matched Description: … investigation in clinical trial NCT02724085 (A Phase 1 Study to Assess the Safety, Tolerability and PK of
Ravoxertinib is under investigation in clinical trial NCT01875705 (A Dose-Escalation Study of GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors).
Investigational
Matched Description: … Ravoxertinib is under investigation in clinical trial NCT01875705 (A Dose-Escalation Study of GDC-0994 …
CXL-1020 is under investigation in clinical trial NCT01092325 (Safety and Hemodynamic Effects and Pharmacokinetics of CXL-1020 in Patients With Stable Heart Failure).
Investigational
Matched Description: … under investigation in clinical trial NCT01092325 (Safety and Hemodynamic Effects and Pharmacokinetics of
BMS-754807 is under investigation in clinical trial NCT00908024 (Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors).
Investigational
Matched Description: … BMS-754807 is under investigation in clinical trial NCT00908024 (Combination Study of BMS-754807 and …
Snubh-nm-333 F-18 is under investigation in clinical trial NCT02149017 (Phase 1 and Phase 2 Clinical Trials of SNUBH-NM-333(18F)).
Investigational
Matched Description: … -333 F-18 is under investigation in clinical trial NCT02149017 (Phase 1 and Phase 2 Clinical Trials of
Dihydromyricetin is under investigation in clinical trial NCT03606694 (Effect of Dihydromirycetin on Glycemic Control, Insulin Sensitivity and Insulin Secretion in Type 2 Diabetes Mellitus).
Investigational
Matched Description: … Dihydromyricetin is under investigation in clinical trial NCT03606694 (Effect of Dihydromirycetin on …
FF-10101-01 is under investigation in clinical trial NCT03194685 (Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia).
Investigational
Matched Description: … FF-10101-01 is under investigation in clinical trial NCT03194685 (Study of FF-10101-01 in Patients With …
PT-2385 is under investigation in clinical trial NCT03108066 (PT2385 for the Treatment of Von Hippel-lindau Disease-associated Clear Cell Renal Cell Carcinoma).
Investigational
Matched Description: … PT-2385 is under investigation in clinical trial NCT03108066 (PT2385 for the Treatment of Von Hippel-lindau …
IDE-196 is under investigation in clinical trial NCT03947385 (Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions).
Investigational
Matched Description: … IDE-196 is under investigation in clinical trial NCT03947385 (Study of IDE196 in Patients With Solid …
Avotaciclib is under investigation in clinical trial NCT03579836 (Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient With Pancreatic Cancer).
Investigational
Matched Description: … Avotaciclib is under investigation in clinical trial NCT03579836 (Evaluation of Safety and Efficacy in …
NDX-3315 is an investigational radiopharmaceutical agent for the diagnosis, treatment monitoring, and management of eosinophilic esophagitis. It is a technetium-99m radiolabeled heparin.
Investigational
Matched Description: … an investigational radiopharmaceutical agent for the diagnosis, treatment monitoring, and management of
N-(4-carbamimidoylbenzyl)-1-(3-phenylpropanoyl)-l-prolinamide is a solid. This compound belongs to the alpha amino acid amides. These are amide derivatives of alpha amino acids. This medication targets the protein prothrombin.
Experimental
Matched Description: … These are amide derivatives of alpha amino acids. This medication targets the protein prothrombin. …
Apomab is under investigation in clinical trial NCT00851136 (A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g)).
Investigational
Matched Description: … Apomab is under investigation in clinical trial NCT00851136 (A Study of PRO95780 Administered in Combination …
Collagen-polyvinylpyrrolidone is a copolymer generated from a mixture of type I collagen and low-molecular-weight PVP that has undergone γ irradiation . It is characterized by antifibrotic, fibrolytic, and immunomodulatory properties .
Investigational
Matched Description: … Collagen-polyvinylpyrrolidone is a copolymer generated from a mixture of type I collagen and low-molecular-weight …
BT200 (Rondoraptivon pegol) is a PEGylated anti-von Willebrand factor (VWF) aptamer targeted against the VWF A1 domain. It is under investigation for the treatment of von Willebrand disease and hemophilia A.
Investigational
Matched Description: … [A261491] It is under investigation for the treatment of von Willebrand disease and hemophilia A. …
VX-702 is a small molecule investigational oral anti-cytokine therapy for treatment of inflammatory diseases, specifically rheumatoid arthritis (RA). It acts as a p38 MAP kinase inhibitor. In the future, VX-702 may be investigated for combination with methotrexate, a commonly used therapy for RA.
Investigational
Matched Description: … VX-702 is a small molecule investigational oral anti-cytokine therapy for treatment of inflammatory diseases …
Cerulenin is an antifungal agent whose activity interferes with or otherwise acts to prevent the formation of fatty acids and sterols. In fatty acid synthesis, reported to bind in equimolar ratio to b-keto-acyl-ACP synthase. In sterol synthesis, inhibits HMG-CoA synthetase activity. It is also shown to inhibit feeding and induce...
Experimental
Matched Description: … Cerulenin is an antifungal agent whose activity interferes with or otherwise acts to prevent the formation of
Mesenchymal stem cells (MSCs) exert their therapeutic effects through multiple modalities, including paracrine factors such as exosomes. Exosomes are nanometer-sized, membrane-bound vesicles secreted for the purpose of cell-cell communication. Once secreted into extracellular fluid, exosomes are taken up by their target cells or carried to distant target sites. Various bioactive...
Investigational
Matched Description: … Exosomes are nanometer-sized, membrane-bound vesicles secreted for the purpose of cell-cell communication ... While many contain a conserved set of proteins, they also carry unique tissue type-specific proteins. ... These exosomes can also consist of VEGF and matrix metalloproteinase-9 (MMP-9) which aid in angiogenesis …
Epratuzumab is a humanized monoclonal antibody derived from the murine IG2a monoclonal antibody, LL2 (EPB-2). This agent may subsequently be well matched for use in oncology and the treatment of inflammatory autoimmune disorders, such as lupus.
Investigational
Matched Description: … This agent may subsequently be well matched for use in oncology and the treatment of inflammatory autoimmune …
Cimicoxib is a selective COX-2 inhibitor being developed by Affectis as a treatment for depression and schizophrenia. If approved, Cimicoxib would be the first drug in decades to treat depression by a new mechanism of action.
Investigational
Matched Description: … If approved, Cimicoxib would be the first drug in decades to treat depression by a new mechanism of action …
RI 624 is a novel humanized monoclonal antibody that blocks nerve growth factor (NGF), a key mediator of acute and chronic pain. RI 624 is being developed by Rinat and is currently in Phase I clinical trials.
Investigational
Matched Description: … 624 is a novel humanized monoclonal antibody that blocks nerve growth factor (NGF), a key mediator of
SNX-5422 is a synthetic, novel, small molecule Hsp90 Inhibitor. As an oral formulation that demonstrates strong efficacy and tolerability, SNX-5422 is positioned as a breakthrough therapy with broad applicability across a wide range of cancers.
Investigational
Matched Description: … tolerability, SNX-5422 is positioned as a breakthrough therapy with broad applicability across a wide range of
Tricaine (as tricaine methanesulfonate) is white powder used for anesthesia, sedation, or euthanasia of fish. It is also the only anesthetic licensed in the United States for use in fin fish that are intended for human consumption.
Vet approved
Matched Description: … Tricaine (as tricaine methanesulfonate) is white powder used for anesthesia, sedation, or euthanasia of
Displaying drugs 7301 - 7325 of 8039 in total